For the past two years of the COVID-19 pandemic, the challenges in global healthcare have been greater than ever. It is the responsibility of healthcare companies to respond. Sanofi has been committed to play its part throughout that period. Our ability to produce and distribute medicines and vaccines that are vital to patients has been maintained or even improved. Since the first day of the pandemic, we have been cooperating with the authorities to develop potential treatments for COVID-19, including vaccines. Following phase 3 booster results, Sanofi and GSK are in discussions with regulatory authorities and plan to submit its data to support regulatory authorizations.

In a world of uncertainty, teams at all levels of our company are mobilized to improve the way we work, adapt our organization as well as seizing opportunities.

This transformation to increase agility and efficiency is critical to the success of our «Play to Win» strategy. In 2021 we succeeded to increase our sales by 7.1% and to grow our business EPS by 15.5%. We are committed to the United Nations Sustainable Development Goals on health and beyond. We are spurred on by the fact that Sanofi is now ranked the second most sustainable healthcare company in the Dow Jones Sustainability Index. Developing medicines and vaccines that address difficult-to-treat diseases is and remains our greatest contribution to society. Consequently, we invested more than 5 billion euros in 2021 in R&D, in addition to 6.8 billion euros allocated to several acquisitions, notably TranslateBio which is becoming our group plateform for the mRNA.

Despite the current context in which we are all living, we are proud of our mission and our resilience.

I thank you for your trust and continuing loyalty.

- Serge Weinberg, Chairman of the Board of Directors

«Sanofi has closed 2021 with a strong performance in the fourth quarter driven by high double-digit sales growth of Dupixent®, which continues to set impressive record sales quarter after quarter. This quarter marks the first time Specialty Care has led our GBUs by sales, highlighting a significant milestone in our transformation.»

- Paul Hudson, CEO
Asthma is one of the most common chronic diseases in children. In the United States, approximately 75,000 children between the ages of 6 and 11 suffer from uncontrolled moderate to severe form of the disease, and many more worldwide. Despite current standard of care being inhaled corticosteroids and bronchodilators, they may keep severe symptoms such as coughing, wheezing, and difficulty to breath.

The phase 3 trial showed an average reduction of asthma attacks by 65%, an improvement of lung function was also observed as early as two weeks and lasted for up to 52 weeks. At 12 weeks, patients taking Dupixent had improved lung function by 5.32 % compared to the placebo. Overall, asthma control improved at 24 weeks, and 81% of patients reported clinically meaningful improvements.

“FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

Vaccines investor event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

On December 1st, Sanofi and key members of the vaccine leadership team held a vaccine investor event to discuss how the company applies the “Play to Win” strategy to seek growth opportunities and build an industry-leading vaccine pipeline. Sanofi confirmed its mid-term sales guidance announced on the 2019 Capital Markets Day, driven by core franchises such as influenza, meningitis, and pediatric vaccines.

In addition, Sanofi is getting ready to launch nirsevimab, a first-class monoclonal antibody to protect all infants against respiratory syncytial virus (RSV). Sanofi has made significant progress in the field of mRNA technology through the recently established Center of Excellence and the acquisition of Translate Bio. The first new vaccine candidates using the mRNA technology will target Flu, RSV in older adults, chlamydia and acne, and are planned to enter the clinic in 2022 and 2023. Sanofi is also working on next generation influenza programs to deliver differentiated flu vaccines that may set a new standard of care, also deploying proprietary machine-learning to explore the potential for better strain selection in the future.

“This FDA approval brings new hope for children who may be suffering from life-threatening asthma attacks. Dupixent has helped to make a difference in the lives of many patients and families across three diseases with underlying type 2 inflammation, with more than 300,000 patients treated globally.”

-Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation

EVENTS

Vaccines investor event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

On December 1st, Sanofi and key members of the vaccine leadership team held a vaccine investor event to discuss how the company applies the “Play to Win” strategy to seek growth opportunities and build an industry-leading vaccine pipeline. Sanofi confirmed its mid-term sales guidance announced on the 2019 Capital Markets Day, driven by core franchises such as influenza, meningitis, and pediatric vaccines.

In addition, Sanofi is getting ready to launch nirsevimab, a first-class monoclonal antibody to protect all infants against respiratory syncytial virus (RSV). Sanofi has made significant progress in the field of mRNA technology through the recently established Center of Excellence and the acquisition of Translate Bio. The first new vaccine candidates using the mRNA technology will target Flu, RSV in older adults, chlamydia and acne, and are planned to enter the clinic in 2022 and 2023. Sanofi is also working on next generation influenza programs to deliver differentiated flu vaccines that may set a new standard of care, also deploying proprietary machine-learning to explore the potential for better strain selection in the future.

“This FDA approval brings new hope for children who may be suffering from life-threatening asthma attacks. Dupixent has helped to make a difference in the lives of many patients and families across three diseases with underlying type 2 inflammation, with more than 300,000 patients treated globally.”

-Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation

EVENTS

Vaccines investor event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

On December 1st, Sanofi and key members of the vaccine leadership team held a vaccine investor event to discuss how the company applies the “Play to Win” strategy to seek growth opportunities and build an industry-leading vaccine pipeline. Sanofi confirmed its mid-term sales guidance announced on the 2019 Capital Markets Day, driven by core franchises such as influenza, meningitis, and pediatric vaccines.

In addition, Sanofi is getting ready to launch nirsevimab, a first-class monoclonal antibody to protect all infants against respiratory syncytial virus (RSV). Sanofi has made significant progress in the field of mRNA technology through the recently established Center of Excellence and the acquisition of Translate Bio. The first new vaccine candidates using the mRNA technology will target Flu, RSV in older adults, chlamydia and acne, and are planned to enter the clinic in 2022 and 2023. Sanofi is also working on next generation influenza programs to deliver differentiated flu vaccines that may set a new standard of care, also deploying proprietary machine-learning to explore the potential for better strain selection in the future.

“This FDA approval brings new hope for children who may be suffering from life-threatening asthma attacks. Dupixent has helped to make a difference in the lives of many patients and families across three diseases with underlying type 2 inflammation, with more than 300,000 patients treated globally.”

-Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation

EVENTS

Vaccines investor event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

On December 1st, Sanofi and key members of the vaccine leadership team held a vaccine investor event to discuss how the company applies the “Play to Win” strategy to seek growth opportunities and build an industry-leading vaccine pipeline. Sanofi confirmed its mid-term sales guidance announced on the 2019 Capital Markets Day, driven by core franchises such as influenza, meningitis, and pediatric vaccines.

In addition, Sanofi is getting ready to launch nirsevimab, a first-class monoclonal antibody to protect all infants against respiratory syncytial virus (RSV). Sanofi has made significant progress in the field of mRNA technology through the recently established Center of Excellence and the acquisition of Translate Bio. The first new vaccine candidates using the mRNA technology will target Flu, RSV in older adults, chlamydia and acne, and are planned to enter the clinic in 2022 and 2023. Sanofi is also working on next generation influenza programs to deliver differentiated flu vaccines that may set a new standard of care, also deploying proprietary machine-learning to explore the potential for better strain selection in the future.

“This FDA approval brings new hope for children who may be suffering from life-threatening asthma attacks. Dupixent has helped to make a difference in the lives of many patients and families across three diseases with underlying type 2 inflammation, with more than 300,000 patients treated globally.”

-Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation

EVENTS

Vaccines investor event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

On December 1st, Sanofi and key members of the vaccine leadership team held a vaccine investor event to discuss how the company applies the “Play to Win” strategy to seek growth opportunities and build an industry-leading vaccine pipeline. Sanofi confirmed its mid-term sales guidance announced on the 2019 Capital Markets Day, driven by core franchises such as influenza, meningitis, and pediatric vaccines.

In addition, Sanofi is getting ready to launch nirsevimab, a first-class monoclonal antibody to protect all infants against respiratory syncytial virus (RSV). Sanofi has made significant progress in the field of mRNA technology through the recently established Center of Excellence and the acquisition of Translate Bio. The first new vaccine candidates using the mRNA technology will target Flu, RSV in older adults, chlamydia and acne, and are planned to enter the clinic in 2022 and 2023. Sanofi is also working on next generation influenza programs to deliver differentiated flu vaccines that may set a new standard of care, also deploying proprietary machine-learning to explore the potential for better strain selection in the future.

“This FDA approval brings new hope for children who may be suffering from life-threatening asthma attacks. Dupixent has helped to make a difference in the lives of many patients and families across three diseases with underlying type 2 inflammation, with more than 300,000 patients treated globally.”

-Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation

EVENTS

Vaccines investor event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

On December 1st, Sanofi and key members of the vaccine leadership team held a vaccine investor event to discuss how the company applies the “Play to Win” strategy to seek growth opportunities and build an industry-leading vaccine pipeline. Sanofi confirmed its mid-term sales guidance announced on the 2019 Capital Markets Day, driven by core franchises such as influenza, meningitis, and pediatric vaccines.

In addition, Sanofi is getting ready to launch nirsevimab, a first-class monoclonal antibody to protect all infants against respiratory syncytial virus (RSV). Sanofi has made significant progress in the field of mRNA technology through the recently established Center of Excellence and the acquisition of Translate Bio. The first new vaccine candidates using the mRNA technology will target Flu, RSV in older adults, chlamydia and acne, and are planned to enter the clinic in 2022 and 2023. Sanofi is also working on next generation influenza programs to deliver differentiated flu vaccines that may set a new standard of care, also deploying proprietary machine-learning to explore the potential for better strain selection in the future.

“This FDA approval brings new hope for children who may be suffering from life-threatening asthma attacks. Dupixent has helped to make a difference in the lives of many patients and families across three diseases with underlying type 2 inflammation, with more than 300,000 patients treated globally.”

-Naimish Patel, M.D. Head of Global Development in Immunology and Inflammation

EVENTS

Vaccines investor event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

On December 1st, Sanofi and key members of the vaccine leadership team held a vaccine investor event to discuss how the company applies the “Play to Win” strategy to seek growth opportunities and build an industry-leading vaccine pipeline. Sanofi confirmed its mid-term sales guidance announced on the 2019 Capital Markets Day, driven by core franchises such as influenza, meningitis, and pediatric vaccines.

In addition, Sanofi is getting ready to launch nirsevimab, a first-class monoclonal antibody to protect all infants against respiratory syncytial virus (RSV). Sanofi has made significant progress in the field of mRNA technology through the recently established Center of Excellence and the acquisition of Translate Bio. The first new vaccine candidates using the mRNA technology will target Flu, RSV in older adults, chlamydia and acne, and are planned to enter the clinic in 2022 and 2023. Sanofi is also working on next generation influenza programs to deliver differentiated flu vaccines that may set a new standard of care, also deploying proprietary machine-learning to explore the potential for better strain selection in the future.
Sanofi’s integrated social impact strategy aims to build a healthier, more resilient world by ensuring access to healthcare for the world’s poorest people and bringing focus to addressing broader unmet needs. Integrated within the Sanofi’s «Play to Win» business strategy, Sanofi’s commitment to society will continue the fight against infectious diseases while accelerating its goals to reduce the environmental impact of its products and its worldwide operations. Sanofi’s Social Impact Strategy focuses on four building blocks aligned with its «Play to Win» core business strategy.

ENSURING AFFORDABLE ACCESS
SUPPORTING VULNERABLE COMMUNITIES
PROTECTING THE PLANET
BUILDING AN INCLUSIVE WORKPLACE

Update from Sanofi on our ESG ratings – 2021

In 2021, Sanofi has announced a new carbon ambition to address climate change. It now intends to achieve net zero greenhouse gas (GHG) emissions across all operations (scope 1, 2 & 3) by 2050 with an interim target to reach carbon neutrality across all scopes by 2030. In addition to these new objectives, Sanofi will continue its efforts to improve access to medicines through Sanofi Global Health and its historical programs on polio and sleeping sickness. Finally, Sanofi is also committed to ensuring that its leaders reflect the communities and patients it serves and is implementing a number of initiatives to foster diversity and inclusion within the company.

In recognition of Sanofi’s ESG strategy implementation, its ESG rankings have been positively updated. These ESG scores measure the degree to which companies’ take into account and manage material Environmental, Social and Governance factors. Sanofi has been ranked second best among the pharma companies by the Dow Jones Sustainability Index (DJSI). It is included in both DJSI World Index and DJSI Europe Index, having been recognized for its performance for the 15th consecutive year. Sanofi ranked best-in-class across four different categories including innovation management, recognizing our work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Sanofi has also been ranked #1 in the pharmaceutical sector in the latest European ESG ranking issued in August 2021 by Vigeo Eiris (part of Moody’s ESG solutions).

Taking bold action against climate change

“We are proud to maintain a leading position among pharma companies. This recognition is a testimony of our strong commitment to CSR. It also demonstrates the strength of our foundations as we roll out our ambitious new commitments to society.”

- Laurent Lhopitaller, Head of ESG Performances.
Enterogermina® has been part of Sanofi’s Consumer Healthcare portfolio for over 60 years. First launched in 1958 in Italy, the brand is now available in more than 80 countries, including Mexico, Vietnam, Brazil, Turkey, Hungary, and Ukraine. A loved and trusted brand, focused on supporting gut health for the whole family, Enterogermina®’s mechanism of reducing gut inflammation and promoting growth of good bacteria contributes to every individual’s natural resilience.

As Enterogermina® champions people’s natural resilience, it has embarked on relevant initiatives to support low-income populations fighting child mortality caused by diarrhea. As part of Sanofi CHC’s Purpose Day activation, Enterogermina®’s advocacy and brand teams work in collaboration with organizations such as Save the Children, Glasswing, Corporación Yanapaquí, Atados and Proyecto Agua Segura in Latin America building water tanks, restoring washing areas in rural schools, donating community filters and increasing water access and sanitation to more than 135,000 people since 2019. These social campaigns have also fueled innovative ways to engage our consumers around the purpose of Sanofi. With our “Buy and Enterogermina donates” campaign launched for the first time in Brazil in 2021 and recently in Mexico, we have seen that a brand with strong social purpose not only improves people’s lives, but ignites business performance, increasing 23% purchase intent.

Our company and our employees are committed to fulfill our corporate ambition to impact 2 billion people in 2025 to avoid infant deaths from diarrhea in the world.

In its country of origin, Italy, Enterogermina® improved the engagement with pharmacists and shopper activations while working for programs such as CARE and strengthened by PIA, which is the sales force activity to focus on in-store activations. The program consists of providing traditional and digital educational tools to close to five-thousand Pharmacists, helping build understanding and relevance of probiotics whilst sustaining Enterogermina®’s premier position as the #1 brand of choice.

Sanofi invests $180 million equity in Owkin's artificial intelligence

Artificial intelligence developer Owkin will collaborate with Sanofi to support Sanofi’s growing oncology product portfolio in core areas such as lung cancer, breast cancer and multiple myeloma.

In order to use artificial intelligence to accelerate medical research in a way that protects privacy, Owkin, a French American startup, has established a global research network supported by federated learning. It enables data scientists to safely connect to decentralized multi-party data sets and train artificial intelligence models without the need to pool data. This approach will complement Sanofi’s emerging strengths in oncology, as the company’s scientists apply cutting-edge technology platforms to design potentially life-changing drugs for cancer patients worldwide.

“Owkin’s unique methodology supports our ambition to leverage data in innovative ways in R&D. We are striving to advance precision medicine to the next level and to discover innovative treatment methods with the greatest benefits for patients.”

- Arnaud Robert, Chief Digital Officer
**SHAREHOLDER INFORMATION**

**Share performance in Paris**

**SANOFI SHARE PRICE TREND**

CAC 40 rebased on the Sanofi share price - Source: Bloomberg

**FIND OUT THE LATEST PUBLICATIONS ONLINE**

**20F ANNUAL REPORT 2021**
Sanofi has filed its Annual Report on Form 20-F to the U.S. Securities and Exchange Commission (SEC) and its Document d’enregistrement universel to the Autorité des Marchés Financiers (AMF) on February 23, 2022. The 2021 Annual Report on Form 20-F, which includes the Annual Financial Report, is made freely available to the public under the conditions provided by the regulations in force and can be consulted in the “Reports & Publications” section of the website and on the SEC and AMF websites.

**INTEGRATED REPORT 2020**
This report provides an overview of how Sanofi’s activities and investments lead to sustainable business performance and provide value for all stakeholders.
Find out all your shareholder and financial publications on our website: https://www.sanofi.com/en/investors/reports-and-publications

**CALENDAR**
- **March 29th, 2022**
  - Immunology event
- **April 28th, 2022**
  - First quarter 2022 results
- **July 28th, 2022**
  - Second quarter 2022 results

**SANOFI STOCK**
- Euronext Paris, compartment A
- Member code: SAN
- ISIN code: FR 0000120578
- Nasdaq
  - Symbol: SNY
  - CUSIP number: 80105N105000

**SHAREHOLDER RELATIONS**
- SANOFI – Shareholder Relations
  - 54 rue La Boétie – 75008 Paris
  - France
- Tel. Europe: +33 (0)1 53 77 45 45
- Tel. U.S.: +1 888 516 3002
- investor.relations@sanofi.com
- sanofi.com/shareholders

**Forward-looking statement:**
This letter contains projections and other forward-looking statements that are not historical facts. Although the management of Sanofi believes that these projections and forward-looking statements, and their underlying assumptions, are reasonable as of the date of this letter, investors are cautioned that such projections, assumptions, intentions and forward-looking statements are subject to various risks and uncertainties (many of which are difficult to predict and generally beyond the control of Sanofi) that could cause actual results and developments to differ materially from those expressed or implied. These risks and uncertainties include the uncertainties inherent in the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate the risks identified in this letter, as well as in the filings of Sanofi with the U.S. Securities and Exchange Commission (SEC) and the French Autorité des marchés financiers (AMF), notably under the caption “Risk Factors” in the company’s annual report on Form 20-F. Other than as required by applicable law, Sanofi does not undertake any obligation to update any statement that is not a historical fact.

Please note that not all products indications described in this document are necessarily in each of the markets in which the products are approved. For specific information, please refer to the full labelling approved in each market.

The Letter to Shareholders is published by Sanofi Investor Relations /Shareholder Relations.